share_log

CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript Summary

CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript Summary

CareDx公司(CDNA)2024年第三季度業績會交易摘要
富途資訊 ·  2024/11/05 11:20  · 電話會議

The following is a summary of the CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript:

以下是caredx, Inc (CDNA) Q3 2024 業績會交易簡報:

Financial Performance:

金融業績:

  • CareDx reported Q3 revenue of $82.9 million, a 23% year-over-year growth.

  • Adjusted EBITDA was $6.9 million, substantially above the EBITDA-neutral guide.

  • Generated $12.5 million in cash from operations and ended with $241 million in cash and cash equivalents.

  • caredx報告Q3的營業收入爲8290萬美元,同比增長23%。

  • 調整後的EBITDA爲690萬美元,遠高於EBITDA中立的指引。

  • 從運營中獲得了1250萬美元的現金,最終現金及現金等價物達24100萬美元。

Business Progress:

業務進展:

  • Delivered approximately 44,600 tests, up 16% from the previous year.

  • Added 15 of a planned 30 sales and marketing team members to promote transplant solutions.

  • Collaboration with the University of California Health System to implement MedActionPlan.

  • 提供了約44,600項測試,比去年增長了16%。

  • 增加了30名計劃內的銷售和市場團隊成員中的15名,以推廣移植解決方案。

  • 與加州大學醫療系統合作,實施MedActionPlan。

Opportunities:

機會:

  • Coverage from Medicare and Medicaid Services reaffirmed for solid organ transplant monitoring.

  • Expanded commercial covered lives by four million in Q3. Highmark Blue Cross Blue Shield recently expanded coverage for AlloSure Kidney and HeartCare.

  • Medicare和Medicaid Services的覆蓋範圍已確認用於固體器官移植監測。

  • 第三季度將商業覆蓋人數擴大了四百萬。Highmark藍十字藍盾最近擴大了AlloSure腎臟和HeartCare心臟的覆蓋範圍。

Risks:

風險:

  • No explicit risks detected.

  • 沒有發現任何明確風險。

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:如需更全面的詳情,請參閱投資人關係網站。本文僅供投資者參考,不作任何指引或建議。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論